The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
- PDF / 932,982 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 1 Downloads / 156 Views
PRACTICAL APPROACH
The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab Jerome Goldschmidt . Vladimir Hanes
Received: September 30, 2020 / Accepted: October 24, 2020 Ó The Author(s) 2020
ABSTRACT ABP 215 (MVASITM, Amgen, Thousand Oaks, CA; MVASITM, Amgen Europe B.V., Netherlands) is a biosimilar to bevacizumab (AvastinÒ, Genentech, South San Francisco, CA) reference product (RP), a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A). Here we provide a brief overview of the totality of evidence that supported the approval of ABP 215, along with practical considerations to ensure safe and effective administration. ABP 215 has been shown to be highly similar to the RP, with similar mechanism of action, analytical (structural and functional) characteristics, binding, and potency. The similarity of PK parameters of ABP 215 and bevacizumab RP has been confirmed in healthy volunteers.
Electronic Supplementary Material The online version of this article (https://doi.org/10.1007/s40487020-00133-1) contains supplementary material, which is available to authorized users. J. Goldschmidt (&) Oncology and Hematology Associates of Southwest Virginia, US Oncology Research, McKesson Specialty Health, Blacksburg, VA, USA e-mail: [email protected] V. Hanes Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA
In a comparative clinical trial, patients with stage IV or recurrent non-squamous non-small cell lung cancer receiving carboplatin and paclitaxel were randomized to ABP 215 or bevacizumab RP. No clinically meaningful differences were found between ABP 215 and RP. The objective response rate (ORR) was 39% for ABP 215 and 41.7% for bevacizumab RP. The risk ratio for the ORR was 0.93 [90% confidence interval (CI), 0.80–1.09], which fell within the prespecified margin for equivalence of 0.67–1.5, indicating similar clinical efficacy. Similar to bevacizumab RP, ABP 215 is supplied as a clear to slightly opalescent, colorless to pale yellow, sterile solution in a glass vial. It should be diluted in 0.9% sodium chloride in polyvinylchloride or polyolefin bags before administering as an intravenous infusion. The ABP 215 solution should be stored at 2–8 °C (36–46°F) prior to use. Physicochemical stability studies showed that there were no meaningful changes in purity or potency and no loss of protein after storage at 2–8 °C for 35 days followed by storage at 30 °C for 48 h.
Keywords: ABP 215; Cervical cancer; Colorectal cancer; Epithelial ovarian cancer; Fallopian tube cancer; Glioblastoma; Nonsmall cell lung cancer; Primary peritoneal cancer; Renal cell carcinoma
Oncol Ther
INTRODUCTION Key Summary Points TM
ABP215 (MVASI ) is a biosimilar to bevacizumab reference product (RP). It is highly similar to the RP in analytical characteristics and, like the RP, binds with high affinity to vascular endothelial growth factor A (VEGF-A), resulting in subsequent inhibition of its binding to endothelial VEGF receptors and downstream inhibition of angiogenesis and multip
Data Loading...
